Cyclohexyl PROTAC Compound for Androgen Receptor Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AR antagonists and PROTAC molecules have limitations in effectively targeting and degrading androgen receptors for treating prostate cancer, necessitating the development of more potent and selective compounds.
Innovation Solution
A compound of formula I-AA, its stereoisomers, or pharmaceutically acceptable salts, featuring specific ring structures and substituents, is designed to target and degrade androgen receptors, leveraging the PROTAC technology for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current AR antagonists are used to treat prostate cancer, then androgen binding is blocked, but therapeutic efficacy is insufficient
Solution Approach 1:
The patent combines two functional modules into a single bifunctional PROTAC molecule: (1) an AR antagonist binding module that binds to the androgen receptor, and (2) an E3 ubiquitin ligase binding module that recruits the proteasome system. This merging enables the single compound to both bind AR and induce degradation, resolving the contradiction between blocking androgen binding and achieving sufficient therapeutic efficacy through degradation.
Solution Approach 2:
The PROTAC molecule performs multiple functions simultaneously: it acts as an AR antagonist to block androgen binding, serves as a molecular glue to induce conformational changes in AR, and recruits E3 ubiquitin ligase to tag AR for degradation. This multi-functionality allows one compound to address multiple therapeutic needs, improving reliability while maintaining adaptability.
2Productivity
If PROTAC molecules are designed to degrade androgen receptors, then degradation activity is enhanced, but selectivity and potency require improvement
Solution Approach 1:
The patent optimizes specific local regions of the PROTAC molecule: the AR antagonist binding module is designed with specific substituent patterns (R1-R6 groups) to enhance binding affinity and selectivity for AR, while the E3 ligase binding module (containing cyclohexyl ring E and aromatic rings F and G) is optimized for selective recruitment of specific E3 ubiquitin ligases. This local optimization ensures high degradation activity with improved selectivity.
Solution Approach 2:
The patent systematically varies structural parameters of the PROTAC molecule, including: (1) different connecting groups L (alkylene chains of varying lengths), (2) different ring structures (aromatic vs. heteroaromatic), (3) different substituent types and positions (R1-R6 groups), and (4) different stereochemical configurations. These parameter changes allow optimization of both degradation activity and selectivity by tuning the molecular properties to achieve optimal binding characteristics.
Data Source
AI summary
The present application relates to a compound containing cyclohexyl, in particular to a compound of formula (I-AA), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof in treating related diseases (such as cancer).